MTOR and malignant peripheral nerve sheath tumor: Another study by Kim et al. (2020) determined the safety, tolerability, and recommended dose of ganetespib (a small molecule inhibitor of HSP90) and sirolimus (mTOR inhibitor) in patients with unresectable/refractory MPNST [92].